Anticancer drug irinotecan is not suitable for everyone
Drugs need to be metabolized through a series of enzymes in the body. Some drugs have low activity after the enzyme metabolism. And some drugs transform into the active form after metabolism. Among them, transfering enzymes of uridine diphosphate glucuronyl are responsible for reducing toxicity of some toxic substances or drugs with a transporter and excreting it. The activity of this enzyme is not the same in different people. Some enzyme activities are strong and the speed of excreting poison is fast. On the contrary, some enzyme activities are weak. So the concentration of poison in the body will maintain at a high level.
Different
metabolic types between different people are due to the different gene encoding
of this enzyme, so that the pharmaceutical raw
materials will play different roles or produce different adverse effects of
the medication of people with different Irinotecan is an anticancer drug used
in clinical trials. Its active ingredient SN-38 is an active enzyme. It becomes
SN
Patients with low
UGT
Some patients with
irinotecan, given the normal recommended dose of time will happen after very
severe neutropenia and diarrhea. The patient can not tolerate the very painful
and even fatal treatment process. Therefore, before applying irinotecan, it is
best to UGT
Irinotecan is used in the treatment of adult metastatic colorectal cancer. And for the patients with failures of 5-Fu chemotherapy, it can be used as a second-line treatment. At the same time, phased observations of a variety of clinical trials in gastric cancer, esophageal cancer, extensive stage small cell lung cancer are underway. In the point of view of interim observations, irinotecan has a good clinical application prospect and it is worth close attention.Source:http://www.cospcn.com